Document is current
Any future updates will be listed below
-
Authors
Ren, Wenfeng https://orcid.org/0009-0001-8073-8720
Xu, Zilong https://orcid.org/0009-0001-5619-5834
Chang, Yating https://orcid.org/0009-0009-6536-8504
Ju, Fei
Wu, Hongning
Liang, Zhiqi
Zhao, Min
Wang, Naizhen
Lin, Yanhua
Xu, Chenhang
Chen, Shengming
Rao, Yipeng
Lin, Chaolong
Yang, Jianxin
Liu, Pingguo https://orcid.org/0000-0001-7177-7333
Zhang, Jun https://orcid.org/0000-0002-6601-9180
Huang, Chenghao https://orcid.org/0000-0001-8267-1307
Xia, Ningshao https://orcid.org/0000-0003-0179-5266
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81991491)
National Natural Science Foundation of China (81991491)
- License Information
-
More Information
Article History
Received: 25 January 2023
Accepted: 14 December 2023
First Online: 2 January 2024
Competing interests
: Xiamen University has filed a patent application covering ‘Application of OTUB2-targeted drugs and methods in cancer immunotherapy’ (No. 202310740647.7). C.H., W.R., Z.X., Y.C., M.Z., H.W., C.X., J.Z. and N.X. are listed as inventors. All other authors declare that they have no competing interests.
